Search Results - "Joshi, Samit"
-
1
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
Published in PloS one (23-10-2018)“…GSK3532795 (formerly known as BMS-955176) is a second-generation maturation inhibitor targeting a specific Gag cleavage site between capsid p24 and spacer…”
Get full text
Journal Article -
2
Viral Drug Resistance through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
Published in Journal of acquired immune deficiency syndromes (1999) (01-03-2018)“…ABSTRACT [Journal limit250 words, currently 250] BACKGROUND:Fostemsavir is a prodrug of temsavir, an attachment inhibitor that binds to HIV-1 gp120, blocking…”
Get full text
Journal Article -
3
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
Published in Antimicrobial agents and chemotherapy (18-05-2021)“…GSK3640254 is a next-generation maturation inhibitor that would likely be combined with standard antiretroviral agents to form a regimen of ≥2 fully active…”
Get full text
Journal Article -
4
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
Published in Clinical infectious diseases (14-09-2022)“…GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily…”
Get full text
Journal Article -
5
Dysregulation of human Toll-like receptor function in aging
Published in Ageing research reviews (01-07-2011)“…Research highlights ► Dysregulation of Toll-like receptor function occurs in aging humans. ► Adjustment for potential confounding factors is critical in human…”
Get full text
Journal Article -
6
Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
Published in British journal of clinical pharmacology (01-09-2021)“…Aims GSK3640254, a novel, next‐generation maturation inhibitor effective against a range of HIV polymorphisms with no cross‐resistance to current…”
Get full text
Journal Article -
7
Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
Published in British journal of clinical pharmacology (01-02-2022)“…Aims GSK3640254 is a next‐generation maturation inhibitor likely to be coadministered with combined oral contraceptives in HIV‐positive women. Methods This…”
Get full text
Journal Article -
8
Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation
Published in Nature neuroscience (01-09-2013)“…Topoisomerases are thought to work in DNA, but not RNA, metabolism. Here Xu et al . describe that Top3A can also act as an RNA topoisomerase and find it in a…”
Get full text
Journal Article -
9
Metabolomic and transcriptomic signatures of influenza vaccine response in healthy young and older adults
Published in Aging cell (01-09-2022)“…Seasonal influenza causes mild to severe respiratory infections and significant morbidity, especially in older adults. Transcriptomic analysis in populations…”
Get full text
Journal Article -
10
Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
Published in PloS one (17-10-2019)“…GSK3532795 (formerly BMS955176) is a second-generation maturation inhibitor (MI) that progressed through a Phase 2b study for treatment of HIV-1 infection…”
Get full text
Journal Article -
11
Prolonged Proinflammatory Cytokine Production in Monocytes Modulated by Interleukin 10 After Influenza Vaccination in Older Adults
Published in The Journal of infectious diseases (01-04-2015)“…We evaluated in vivo innate immune responses in monocyte populations from 67 young (aged 21-30 years) and older (aged ≥65 years) adults before and after…”
Get full text
Journal Article -
12
Multiple network-constrained regressions expand insights into influenza vaccination responses
Published in Bioinformatics (Oxford, England) (15-07-2017)“…Systems immunology leverages recent technological advancements that enable broad profiling of the immune system to better understand the response to infection…”
Get full text
Journal Article -
13
Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
Published in Clinical pharmacology in drug development (01-05-2022)“…GSK3640254 is a next‐generation maturation inhibitor with demonstrated potency across HIV‐1 subtypes and a high barrier to emergent resistance. This phase I,…”
Get full text
Journal Article -
14
Exploring HIV-1 Maturation: A New Frontier in Antiviral Development
Published in Viruses (06-09-2024)“…HIV-1 virion maturation is an essential step in the viral replication cycle to produce infectious virus particles. Gag and Gag-Pol polyproteins are assembled…”
Get full text
Journal Article -
15
Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
Published in Pharmacology research & perspectives (01-12-2020)“…Despite advances in HIV‐1 management with antiretroviral therapy, drug resistance and toxicities with multidrug regimens can result in treatment failure…”
Get full text
Journal Article -
16
Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
Published in Pharmacology research & perspectives (01-12-2023)“…GSK3640254 (GSK'254) is a novel HIV‐1 maturation inhibitor with pharmacokinetics supporting once‐daily (QD) therapy for HIV‐1 treatment. This thorough…”
Get full text
Journal Article -
17
Aging-dependent alterations in gene expression and a mitochondrial signature of responsiveness to human influenza vaccination
Published in Aging (Albany, NY.) (01-01-2015)“…To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age≥65)…”
Get full text
Journal Article -
18
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
Published in The lancet HIV (01-10-2015)“…Summary Background BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells…”
Get full text
Journal Article -
19
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial
Published in Antiviral therapy (01-01-2017)“…Fostemsavir is a prodrug of temsavir, an attachment inhibitor that binds directly to HIV-1 gp120, blocking initial viral attachment and entry into host CD4…”
Get more information
Journal Article -
20
Multicolor Digital Flow Cytometry in Human Translational Immunology
Published in Methods in molecular biology (Clifton, N.J.) (2015)“…By facilitating the simultaneous analysis of parameters from diverse cell lineages and biological pathways, multicolor flow cytometry is integral to many…”
Get more information
Journal Article